Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Formulation and In vitro Evaluation of Transdermal Drug Delivery System for Galantamine

  • Hossain, Md. Kamal (BK21 Project Team, College of Pharmacy, Chosun University) ;
  • Subedi, Robhash Kusam (BK21 Project Team, College of Pharmacy, Chosun University) ;
  • Chun, Myung-Kwan (BK21 Project Team, College of Pharmacy, Chosun University) ;
  • Kim, Eun-Jung (BK21 Project Team, College of Pharmacy, Chosun University) ;
  • Moon, Hwan-Shik (BK21 Project Team, College of Pharmacy, Chosun University) ;
  • Choi, Hoo-Kyun (BK21 Project Team, College of Pharmacy, Chosun University)
  • Received : 2011.01.04
  • Accepted : 2011.01.26
  • Published : 2011.02.20
Download PDF
⟨ Previous Next ⟩

Abstract

The effects of different formulation variables including pressure sensitive adhesive (PSA), permeation enhancer, thickness of the matrix and loading amount of drug on the transdermal absorption of galantamine were investigated across the hairless mouse skin. The permeation profile of galantamine was different depending on the types of PSA, loading amount of drug, thickness of the matrix and type of enhancer used. Highest flux of galantamine was obtained from acrylic PSA but crystals were formed in the patch within 72 h. Among the PSAs screened, crystal formation was not observed only in the patches formulated in Styrene Butadiene Styrene (SBS) matrix. Permeation rate increased linearly as the concentration of galantamine in SBS matrix increased from 2.5 to 15% w/w. Among the enhancers screened, Brij$^{(R)}$ 30 provided highest flux of galantamine. Matrix thickness of 80 ${\mu}m$ was optimum for maintaining adhesiveness as well as consistently delivering galantamine for longer period of time.

Keywords

References

  1. Ang, C., Fen, H.E., Sub, H.E., 2006. Pharmacokinetics of galantamine Hbr in plasma and brain of mice. Chin. J. Pharm. 37, 55-61.
  2. Bankar, U.V., Osborne, D.W., 1995. Transdermal drug product development. Technomic Publishing AG, Switzerland. 165-179.
  3. Breuer, M.M., 1979. The interaction between surfactants and keratinous tissues. J. Soc. Cosmet. 30, 41-64.
  4. Bohn, M., Kraemer, K.T., 2000. Dermatopharmacology of ciclopirox nail laquer topical solution 8% in the treatment of onychomycosis. J. Am. Aca. Dermatol. 43, 57-69. https://doi.org/10.1067/mjd.2000.109072
  5. Cho, Y.-J., Choi, H.-K., 1998. Enhancement of percutaneous absorption of ketoprofen: Effect of vehicles and adhesive matrix. Int. J. Pharm. 169, 95-104. https://doi.org/10.1016/S0378-5173(98)00115-X
  6. Choi, H-K., Angello, J., 1994. The Mathematical analysis and optimization of a flow through diffusion cell system. Pharm. Res. 11, 595-599. https://doi.org/10.1023/A:1018991221647
  7. Corey-Bloom, J., 2003. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int. J. Clin. Pract. 57, 219-223.
  8. Coyle, J., Kershaw, P., 2001. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimers disease. Biol. Psychiatry. 49, 289-299 https://doi.org/10.1016/S0006-3223(00)01101-X
  9. Cummings, J.L., 2003. Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations. Am. J. Geriatr. Psychiatry. 11, 131-145.
  10. Erkinjuntti, T., 2002. Treatment options: The latest evidence with galantamine. J. Neurol .Sci. 203, 125-130. https://doi.org/10.1016/S0022-510X(02)00267-8
  11. Fulton, B., Benfield, P., 1996. Galanthamine. Drugs & Aging. 9, 60-67. https://doi.org/10.2165/00002512-199609010-00006
  12. Furuishi, T., Io, T., Fukami, T., Suzuki, T., Tomono, K., 2008. Formulation and in vitro evaluation of pentazocine transdermal drug delivery system. Biol. Pharm. Bull. 31, 1439-1443. https://doi.org/10.1248/bpb.31.1439
  13. Ghosh, T.K., Pfister, W.R., Yum, S.I., 1997. Transdermal and topical drug delivery systems. In: Pfister, W.R. (Ed.), Transdermal and Dermal Therapeutic Systems. Current Status. Interpharm Press, Illinois. 38-59.
  14. Heinrich, M., Teoh, H.L., 2004. Galantamine from snowdrop the development of a modern drug against Alzheimers disease from local Caucasian knowledge. J. Ethnopharmacol. 92, 147-162. https://doi.org/10.1016/j.jep.2004.02.012
  15. Imani, M., Fard, F.L., Taghezade, S.M., Takrousta, M., 2010. Effect of adhesive layer thickness and drug loading on estradiol Crystallization in a Transdermal Drug Delivery System. AAPS Pharm Sci Tech. 11, 1268-1275. https://doi.org/10.1208/s12249-010-9494-9
  16. Inoue, K., Okada, J., Sugibayashi, K., 2005. Enhancement of skin permeation of ketoprofen by supersaturation generated by amorphous form of the drug. J. Control. Release. 108, 306-318. https://doi.org/10.1016/j.jconrel.2005.08.008
  17. Kays, L.A., Sileno, A.P., Brandt, G.C., Foerder, C.A., Quay, S.C., 2007. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int. J. Pharm. 335, 138-146. https://doi.org/10.1016/j.ijpharm.2006.11.013
  18. Kim, J.-H., Lee, C.H., Choi, H.-K., 2002. Transdermal delivery of physostigmine: Effect of enhancer and pressure sensitive adhesives. Drug Dev. Ind. Pharm. 28, 833-839. https://doi.org/10.1081/DDC-120005629
  19. Kim, J.-H., Cho Y.-J., Choi, H.-K., 2000. Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. Int. J. Pharm. 196, 105-113. https://doi.org/10.1016/S0378-5173(99)00449-4
  20. Migliaccio, W.K., Getsios, D., Caro, J.J., Ishak, K.J., Brien, J.A.O., Papadopoulos, G., 2003. Economic evaluation of galantamine in the treatment of mild to moderate $Alzheimer^{\circ}Os$ disease in the United States. Clin. Ther. 25, 1806-1825. https://doi.org/10.1016/S0149-2918(03)80171-6
  21. Morimoto, Y., Kokubo, T., Sugibayashi, K., 1992. Diffusion of drug in acrylic type pressure sensitive adhesive matrix. II. Influence of interaction. J. Control. Release. 18, 113-121. https://doi.org/10.1016/0168-3659(92)90180-Y
  22. Nordberg, A., Svensson, A.L., 1999. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Safety. 20, 146.
  23. Poirier, J., 2002. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int. J. Clin. Pract. Suppl. 127, 6-19.
  24. Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W., 2000. Galantamine in AD, a 6-month randomized, placebo-controlled trial with a 6-month extension. The galantamine USA-1 Study Group. Neurology. 54, 2261-2268. https://doi.org/10.1212/WNL.54.12.2261
  25. Roy, S.D., Gutierrez, M., Flynn, G.L., Cleary G.W., 1996. Controlled transdermal delivery of fentanyl: Characterizations of pressure sensitive adhesives for matrix patch design. J. Pharm. Sci., 85, 491-495. https://doi.org/10.1021/js950415w
  26. Scott, L.J., Goa, K.L., 2000. Galantamine: a review of its use in Alzheimer’s disease. Drugs. 60, 1095-1122. https://doi.org/10.2165/00003495-200060050-00008
  27. Sramek, J.J., Frackiewicz, E.J., Cutler, N.R., 2000. Review of acetylcholinesterase inhibitor galantamine. Expert Opin. Investig. Drugs. 9, 2393-2402. https://doi.org/10.1517/13543784.9.10.2393
  28. Subedi, R.K., Jang, J.H., Kim, Jae-II, Park, Y.J., Choi, H.-K., 2010. Formulation and evaluation of transdermal patch containing sibutramine. J. Kor. Pharm. Sci. 40, 33-38.
  29. Subedi, R.K., Seaung, Y.O., Chun, M.K., Choi, H.-K., 2010. Recent Advances in Transdermal Drug Delivery. Arch. Pharm. Res. 33, 339-351. https://doi.org/10.1007/s12272-010-0301-7
  30. Thomas, B.J., Finnin, F.C., 2004. The transdermal revolution. Drug Discov. Today. 9, 697-703. https://doi.org/10.1016/S1359-6446(04)03180-0
  31. Walters, K.A., Walker, M., Olejnik, O., 1987. Non-ionic surfactant effects on hairless mouse skin permeability characteristics. J. Pharm. Pharmacol. 40, 525-529.
  32. Wilking, S.M., Husberg, M.L., Ko, C.U., Wick, S.M., 1994. The effect of excipients on the physical properties of selected acrylate, polyisobutylene and silicone pressure sensitive adhesives commonly utilized in transdermal 20 drug delivery systems. Pharm. Res. 11, S226. https://doi.org/10.1023/A:1018999106684
  33. Williams, A.C., Barry, B.W., 2004. Penetration enhancers. Adv. Drug Deliver. Rev. 56, 603-618. https://doi.org/10.1016/j.addr.2003.10.025
  34. Wokovich, A.M., Prodduturi, S., Doub, W.H., Hussain, A.S., Buhse, L.F., 2006. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur. J. Pharm. Biopharm. 64, 1-8. https://doi.org/10.1016/j.ejpb.2006.03.009
  35. Zarotsky, V., Sramek, J.J., Cutler, N.R., 2001. Galantamine hydrobromide: an agent for Alzheimer’s disease. Am. J. Health-Syst. Pharm. 60, 446-452.

Cited by

  1. Development of cataplasmic transdermal drug delivery system containing eutectic mixture of lidocaine and prilocaine vol.42, pp.3, 2012, https://doi.org/10.1007/s40005-012-0023-6